Savara Inc Payments to Acquire Available-for-sale Securities
Savara Inc (SVRA) reported Payments to Acquire Available-for-sale Securities of $15.89 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-05-09
- Savara Inc payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $15.89M.
- Savara Inc payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $43.42M.
- Savara Inc payments to acquire available-for-sale securities for fiscal 2017 was $76.86M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-03-31 | $15.89M 10-Q · filed 2018-05-09 | $59.31M derived: sum of 2 quarters · filed 2018-05-09 | ||
| 2017-12-31 | $43.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $76.86M 10-K · filed 2018-03-14 | ||
| 2017-09-30 | $33.44M 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |